Widespread anticoagulant undertreatment persists among atrial fibrillation (AFib) patients at high risk of stroke, despite current medical treatment guidelines, which recommend thromboprophylaxis for this patient population unless contraindicated, according to a recent study in BMC Health Services Research.
Widespread anticoagulant undertreatment persists among atrial fibrillation (AFib) patients at high risk of stroke, despite current medical treatment guidelines, which recommend thromboprophylaxis for this patient population unless contraindicated, according to a recent study in BMC Health Services Research.
Retrospective data analyses were performed using the Anticoagulant Quality Improvement Analyzer (AQuIA), a software tool designed to analyze health plan data. Two-year data from 5 databases were analyzed: IMS LifeLink, MarketScan Commercial, MarketScan Medicare Supplemental, ClinformaticsTM DataMart, a product of OptumInsight Life Sciences and a Medicaid Database. Key study measures included stroke risk level, anticoagulant use, and frequency of International Normalized Ratio (INR) monitoring.
High stroke risk (CHADS2 ≥ 2 points) was estimated in 54% (IMS), 22% (MarketScanCommercial), 64% (MarketscanMedicare), 42% (Optum) and 62% (Medicaid) of the total eligible population. Overall, 35%, 29%, 38%, 39% and 16% of all AF patients received an anticoagulant medication in IMS, MarketScanCommercial, MarketScanMedicare, Optum and Medicaid, respectively. At best only 51% of AFib patients at high risk of stroke receive treatment with an anticoagulant, despite current medical treatment guidelines, which recommend thromboprophylaxis for this patient population unless contraindicated.
AFib, the most common clinically significant cardiac rhythm disorder, increases a patient’s risk for stroke up to 5-fold, directly or indirectly contributing to more than $30 billion in annual healthcare costs, lead investigator Winnie Nelson, director, Health Economics & Outcomes Research, at Janssen Pharmaceuticals.
“Appropriate treatment, such as with an oral anticoagulant, has been shown to reduce the annual incidence of stroke in the United States by more than 60%, which may lead to decreased mortality rates and hospital cost savings,” Nelson said.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More